Sudden loss in kidney function and increasing serum creatinine level without loss of urine are observed in ICU-acquired acute kidney. It is observed in people who have been admitted in the ICU for a particular treatment.
The ICU-acquired acute kidney treatment market is segmented based on type, therapy type and regions. On the basis on type, the market is divided into pre-renal, intrinsic-renal and post-renal. Based on therapy type, the market is segmented into intermittent hemodialysis, continuous renal replacement therapy and sustained low-efficiency dialysis.
With the COVID-19 breakout in December 2019, the disease has affected more than 200 countries. Therefore, it is important to take this into consideration while addressing ICU-acquired acute kidney treatment market.
The disease may have led to temporary lag in the ICU-acquired acute kidney treatment market, but in the long run the ICU-acquired acute kidney treatment market is expected to pace up and flourish at a significant rate during the forecast period 2020-2030.
Increasing prevalence of lifestyle-related diseases such as obesity & diabetes and rising incidence of renal failure cases are the major factors that are expected to drive the growth of the ICU-acquired acute treatment market.
Moreover, the rising geriatric population, increasing health expenditure among the population, increasing initiatives by the government to manage chronic kidney diseases and technological advancement in the healthcare sector may also boost the growth of the ICU-acquired acute treatment market.
However, stringent rules by various health authority for product approvals and low awareness regarding treatment in developing and underdeveloped countries may hinder the growth of the ICU-acquired acute kidney treatment market.
On the basis of treatment type,the ICU-acquired acute kidney treatment market is segmented into pre-renal, intrinsic-renal and post renal. In this segment, intrinsic-renal is expected to be the major contributor of revenue and will lead to the growth of ICU-acquired acute kidney treatment market.
On the basis of therapy type, the ICU-acquired acute kidney treatment market is segmented into intermittent hemodialysis, continuous renal replacement therapy and sustained low-efficiency dialysis. In this segment, intermittent hemodialysis may continue to grow as it is highly effective in achieving solute removal.
The global ICU-acquired acute kidney treatment market is segmented into 5 regions i.e. North America, Latin America, Europe, Asia-Pacific and Middle East &Africa. North America is expected to dominate the ICU-acquired acute kidney treatment market in terms of revenue during the forecast period due to growing no. of research activities and availability of drugs for treatment of the disease in this region.
Europe is expected to be 2nd highest contributor in terms of revenue in the ICU-acquired acute kidney treatment market. On the other hand, Asia Pacific is expected to experience fastest growth in the ICU-acquired acute kidney treatment market as a result of rising no. of kidney disorders, increasing geriatric population and higher investment for better healthcare facilities in countries in this region.
The growth of the ICU-acquired acute kidney treatment market is expected to be limited in the Middle East & Africa due to slow economic growth and limited development in healthcare sector.
Some of the players identified in the ICU-acquired acute kidney treatment market include:
The globalICU-acquired acute kidney treatment markethas been segmented on the basis oftreatment type, application and end user.
Treatment Type:
Therapy Type:
Region:
Explore Similar Insights
ICU-acquired Acute Kidney Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
